Shire PLC (SHPG)

154.76
1.40 0.89
NASDAQ : Health Care
Prev Close 153.40
Open 152.97
Day Low/High 152.94 / 154.74
52 Wk Low/High 147.60 / 270.63
Volume 321.57K
Avg Volume 1.33M
Exchange NASDAQ
Shares Outstanding 302.76M
Market Cap 47.08B
EPS 1.30
P/E Ratio 42.26
Div & Yield 0.31 (0.20%)

Latest News

Biotech Movers: Red Hill Jumps After Securing Rights Sell GERD Treatment

Biotech Movers: Red Hill Jumps After Securing Rights Sell GERD Treatment

A number of biotech-related stocks were down pre-market after announcing plans for public offerings.

Shire Gains as it Seeks European Approval For Dry Eye Treatment

Shire Gains as it Seeks European Approval For Dry Eye Treatment

The drug would be the first such treatment in Europe.

Tesla and Apple Better Deliver Big-Time or Look Out Below -- Week Ahead

Tesla and Apple Better Deliver Big-Time or Look Out Below -- Week Ahead

The labor market goes under inspection and Apple releases its earnings report.

Shire Stock Rising on Takeover Talks

Shire Stock Rising on Takeover Talks

Shire is also said to have hired its own defense advisers to ward off low bids.

7 Potential New Targets for Activist Investor That Made a Killing on Whole Foods

7 Potential New Targets for Activist Investor That Made a Killing on Whole Foods

Here are the activist investor's next potential targets.

Jana Partners Liquidates Whole Foods Stake After Engineering Industry-Transforming Sale To Amazon

Jana Partners Liquidates Whole Foods Stake After Engineering Industry-Transforming Sale To Amazon

The activist will gain $320 million on the sale, which suggests that the fund either doesn't believe a higher bidder is coming or that they need the cash.

Arena Pharma's Stock Could Still Double Even After Tuesday's Epic Run

Arena Pharma's Stock Could Still Double Even After Tuesday's Epic Run

Big gains could be ahead for investors willing to stick with the stock, according to one firm.

Biotech Movers: Shire, Bellicum, Organovo

Biotech Movers: Shire, Bellicum, Organovo

Shire, Bellicum Pharmaceuticals and Organovo Holdings were among the biotech stock movers in premarket trading on June 22.

Shire Plc: U.S. FDA Approves Mydayis[TM] (Mixed Salts Of A Single-Entity Amphetamine Product) - A New Once-Daily Option For ADHD Symptom Control In Patients 13 Years And Older

Mydayis demonstrated improvements lasting up to 16 hours post-dose, beginning at 2 or 4 hours post-administration, compared to placebo, in total score on a skill-adjusted math test that measures attention in ADHD

The Activist Who Pushed Whole Foods Into the Arms of Amazon Could Target These Companies Next

The Activist Who Pushed Whole Foods Into the Arms of Amazon Could Target These Companies Next

Here are the activist investor's next potential targets.

Biotech Movers: Shire Falls on Stem Cell Program Transfer; Calithera, Synergy Up on FDA Approvals

Biotech Movers: Shire Falls on Stem Cell Program Transfer; Calithera, Synergy Up on FDA Approvals

Plus more from the biotechnology world on Wednesday, June 7.

Biotech Movers: Fast Track Designation Sends Sage Shares Higher

Biotech Movers: Fast Track Designation Sends Sage Shares Higher

Sage Therapeutics, Incyte and Shire were among the biotech movers in premarket trading on Thursday.

Shire Stock Rises Premarket on Positive Phase 3 Results for Angiodema Treatment

Shire Stock Rises Premarket on Positive Phase 3 Results for Angiodema Treatment

The study tested the drug on patients aged 12 years and older for 26 weeks.

Shire Continues 20-Year Commitment To ADHD With New Research At 2017 Annual Meeting Of American Psychiatric Association

Latest Research Supports Greater Understanding of the Evolving Needs of Adults with ADHD

Shire Granted EU Conditional Marketing Authorisation For Natpar[®¿] (Parathyroid Hormone) For The Treatment Of Patients With Chronic Hypoparathyroidism

Natpar is the first and only licensed recombinant human parathyroid hormone therapy for chronic hypoparathyroidism

Shire Launches #PIPostsThanks Social Campaign To Raise Awareness Of Primary Immunodeficiency (PI)

Shire launches campaign to raise global awareness during World PI Week

What to Expect From European Pharmaceuticals' First Quarter Results

What to Expect From European Pharmaceuticals' First Quarter Results

New drug launches and late stage trials will be under the microscope as eight European pharmaceuticals companies report Q1 earnings starting next week.

TheStreet Quant Rating: C- (Hold)